Unmanipulated or CD34 selected haplotype mismatched transplants

Area of Science:

• Hematopoietic Stem Cell Transplantation
• Immunology
• Oncology

Background:

• Haploidentical stem cell transplantation (HSCT) is crucial for patients lacking human leukocyte antigen (HLA)-matched siblings or requiring urgent transplants.
• Delayed immune reconstitution post-HSCT increases risks of opportunistic infections.
• This review examines strategies to optimize HSCT outcomes.

Purpose of the Study:

• To summarize recent research on optimizing outcomes in unmanipulated or CD34 selected haplotype mismatched transplantation.
• To highlight advancements in addressing challenges associated with HSCT.

Main Methods:

• Review of recent investigations into HSCT protocols.
• Analysis of graft types, including T-cell-depleted or unmanipulated progenitor cells.
• Evaluation of conditioning regimens, including high-intensity and reduced-intensity approaches.

Main Results:

• Reduced-intensity conditioning regimens show promise in decreasing mortality and expanding HSCT eligibility to older patients with comorbidities.
• Natural killer (NK) cell alloreactivity can mitigate graft-versus-host disease (GVHD) while enhancing graft-versus-malignancy (GVM).
• Immune reconstitution status is a strong predictor of outcomes after T-cell-depleted HSCT.

Conclusions:

• Mismatched/haploidentical HSCT is a viable alternative for high-risk hematological malignancies and marrow failure syndromes.
• Survival rates and clinical outcomes are improving with ongoing research.
• Future research should focus on optimizing preparative regimens, minimizing GVHD, preserving GVM, and promoting rapid immune reconstitution.